JP2017500364A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017500364A5 JP2017500364A5 JP2016542969A JP2016542969A JP2017500364A5 JP 2017500364 A5 JP2017500364 A5 JP 2017500364A5 JP 2016542969 A JP2016542969 A JP 2016542969A JP 2016542969 A JP2016542969 A JP 2016542969A JP 2017500364 A5 JP2017500364 A5 JP 2017500364A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- pyrazol
- benzo
- amine
- triazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 1-hydroxymethylpropyl Chemical group 0.000 claims description 588
- 150000001875 compounds Chemical class 0.000 claims description 85
- 229910052736 halogen Inorganic materials 0.000 claims description 78
- 150000002367 halogens Chemical class 0.000 claims description 67
- 125000000217 alkyl group Chemical group 0.000 claims description 60
- 125000003545 alkoxy group Chemical group 0.000 claims description 34
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 34
- 125000000623 heterocyclic group Chemical group 0.000 claims description 33
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 32
- 125000005842 heteroatom Chemical group 0.000 claims description 29
- 229910052717 sulfur Inorganic materials 0.000 claims description 25
- 229910052760 oxygen Inorganic materials 0.000 claims description 24
- 150000001412 amines Chemical class 0.000 claims description 22
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 claims description 20
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 230000003463 hyperproliferative effect Effects 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 13
- 125000001072 heteroaryl group Chemical group 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
- KRZJRNZICWNMOA-GXSJLCMTSA-N (3s,4r)-4,8-dihydroxy-3-methoxy-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1=CC=C2[C@@H](O)[C@@H](OC)CC(=O)C2=C1O KRZJRNZICWNMOA-GXSJLCMTSA-N 0.000 claims description 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 10
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 8
- 208000027866 inflammatory disease Diseases 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 5
- HNEGJTWNOOWEMH-UHFFFAOYSA-N 1-fluoropropane Chemical group [CH2]CCF HNEGJTWNOOWEMH-UHFFFAOYSA-N 0.000 claims description 4
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 claims description 4
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 208000008035 Back Pain Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 4
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 201000003068 rheumatic fever Diseases 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 3
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 claims description 3
- XNEKZHJLYPYEDG-FQEVSTJZSA-N (2R)-2-(4-chloro-3-fluorophenyl)-2-[5-[2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]benzotriazol-1-yl]ethanol Chemical compound ClC1=C(C=C(C=C1)[C@H](CO)N1N=NC2=C1C=CC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C)F XNEKZHJLYPYEDG-FQEVSTJZSA-N 0.000 claims description 2
- YEFNKKDOWBFTTN-OAHLLOKOSA-N (2R)-3-[[4-[1-[(3-fluoro-4-methoxyphenyl)methyl]benzotriazol-5-yl]pyrimidin-2-yl]amino]propane-1,2-diol Chemical compound FC=1C=C(CN2N=NC3=C2C=CC(=C3)C2=NC(=NC=C2)NC[C@H](CO)O)C=CC=1OC YEFNKKDOWBFTTN-OAHLLOKOSA-N 0.000 claims description 2
- RVUUULZWVYEJQP-HXUWFJFHSA-N (2S)-2-(3-fluoro-4-methoxyphenyl)-2-[5-[2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]benzotriazol-1-yl]ethanol Chemical compound FC=1C=C(C=CC=1OC)[C@@H](CO)N1N=NC2=C1C=CC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C RVUUULZWVYEJQP-HXUWFJFHSA-N 0.000 claims description 2
- XNEKZHJLYPYEDG-HXUWFJFHSA-N (2S)-2-(4-chloro-3-fluorophenyl)-2-[5-[2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]benzotriazol-1-yl]ethanol Chemical compound ClC1=C(C=C(C=C1)[C@@H](CO)N1N=NC2=C1C=CC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C)F XNEKZHJLYPYEDG-HXUWFJFHSA-N 0.000 claims description 2
- WDIUOJIBIYQMOP-ZDUSSCGKSA-N (2S)-2-[[4-[1-[(3-fluoro-4-methoxyphenyl)methyl]benzotriazol-5-yl]pyrimidin-2-yl]amino]propan-1-ol Chemical compound FC=1C=C(CN2N=NC3=C2C=CC(=C3)C2=NC(=NC=C2)N[C@H](CO)C)C=CC=1OC WDIUOJIBIYQMOP-ZDUSSCGKSA-N 0.000 claims description 2
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims description 2
- WEUQDDHRMRKJFE-UHFFFAOYSA-N 1-[[4-[1-[(3-fluoro-4-methoxyphenyl)methyl]benzotriazol-5-yl]pyrimidin-2-yl]amino]-2-methylpropan-2-ol Chemical compound FC=1C=C(CN2N=NC3=C2C=CC(=C3)C2=NC(=NC=C2)NCC(C)(O)C)C=CC=1OC WEUQDDHRMRKJFE-UHFFFAOYSA-N 0.000 claims description 2
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 claims description 2
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 2
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 claims description 2
- JYYNAJVZFGKDEQ-UHFFFAOYSA-N 2,4-Dimethylpyridine Chemical compound CC1=CC=NC(C)=C1 JYYNAJVZFGKDEQ-UHFFFAOYSA-N 0.000 claims description 2
- 125000006507 2,4-difluorobenzyl group Chemical group [H]C1=C(F)C([H])=C(F)C(=C1[H])C([H])([H])* 0.000 claims description 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 claims description 2
- NYWWLAGHUMTSBB-UHFFFAOYSA-N 2-methoxy-1-oxidopyridin-1-ium Chemical compound COC1=CC=CC=[N+]1[O-] NYWWLAGHUMTSBB-UHFFFAOYSA-N 0.000 claims description 2
- STDJZPGBULTFDY-UHFFFAOYSA-N 2-methyl-1-[5-[2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]benzotriazol-1-yl]propan-2-ol Chemical compound CC(CN1N=NC2=C1C=CC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C)(C)O STDJZPGBULTFDY-UHFFFAOYSA-N 0.000 claims description 2
- CYKNJZXYPCRKLB-UHFFFAOYSA-N 3-[[4-[1-[(3-fluoro-4-methoxyphenyl)methyl]benzotriazol-5-yl]pyrimidin-2-yl]amino]-2,2-dimethylpropan-1-ol Chemical compound FC=1C=C(CN2N=NC3=C2C=CC(=C3)C2=NC(=NC=C2)NCC(CO)(C)C)C=CC=1OC CYKNJZXYPCRKLB-UHFFFAOYSA-N 0.000 claims description 2
- 125000000984 3-chloro-4-fluorobenzyl group Chemical group [H]C1=C(F)C(Cl)=C([H])C(=C1[H])C([H])([H])* 0.000 claims description 2
- 125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 claims description 2
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 claims description 2
- RDKGKKJJOWUXDF-UHFFFAOYSA-N 4-[1-(2,2-difluoroethyl)benzotriazol-5-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound FC(CN1N=NC2=C1C=CC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C)F RDKGKKJJOWUXDF-UHFFFAOYSA-N 0.000 claims description 2
- HCHMWZLELDYETC-UHFFFAOYSA-N 4-[1-(2,2-difluoropropyl)benzotriazol-5-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound FC(CN1N=NC2=C1C=CC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C)(C)F HCHMWZLELDYETC-UHFFFAOYSA-N 0.000 claims description 2
- VQGLNWPGWZQMQI-UHFFFAOYSA-N 4-[1-(2-ethylbutyl)benzotriazol-5-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical class CCC(CC)CN1N=NC2=CC(=CC=C12)C1=CC=NC(NC2=CC=NN2C)=N1 VQGLNWPGWZQMQI-UHFFFAOYSA-N 0.000 claims description 2
- BSLOZWRSVSMZKZ-UHFFFAOYSA-N 4-[1-(2-methoxy-2-methylpropyl)benzotriazol-5-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound COC(CN1N=NC2=C1C=CC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C)(C)C BSLOZWRSVSMZKZ-UHFFFAOYSA-N 0.000 claims description 2
- RJBWQPWJJXUJRG-UHFFFAOYSA-N 4-[1-(2-methylbutyl)benzotriazol-5-yl]-N-(1-methylpyrazol-4-yl)pyrimidin-2-amine Chemical class CN1N=CC(=C1)NC1=NC=CC(=N1)C1=CC2=C(N(N=N2)CC(CC)C)C=C1 RJBWQPWJJXUJRG-UHFFFAOYSA-N 0.000 claims description 2
- DQFORPABSRBOKI-UHFFFAOYSA-N 4-[1-(2-methylbutyl)benzotriazol-5-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical class CN1N=CC=C1NC1=NC=CC(=N1)C1=CC2=C(N(N=N2)CC(CC)C)C=C1 DQFORPABSRBOKI-UHFFFAOYSA-N 0.000 claims description 2
- ZFXUMILMBOIHCX-UHFFFAOYSA-N 4-[1-(2-methylpropyl)benzotriazol-5-yl]-N-(1-methylpyrazol-4-yl)pyrimidin-2-amine Chemical compound C(C(C)C)N1N=NC2=C1C=CC(=C2)C1=NC(=NC=C1)NC=1C=NN(C=1)C ZFXUMILMBOIHCX-UHFFFAOYSA-N 0.000 claims description 2
- LUAXHBSGWJGLEK-UHFFFAOYSA-N 4-[1-(2-methylpropyl)benzotriazol-5-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound C(C(C)C)N1N=NC2=C1C=CC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C LUAXHBSGWJGLEK-UHFFFAOYSA-N 0.000 claims description 2
- NLPLKXWLYFWCFF-UHFFFAOYSA-N 4-[1-(2-methylpropyl)benzotriazol-5-yl]-N-(2-methyltriazol-4-yl)pyrimidin-2-amine Chemical compound C(C(C)C)N1N=NC2=C1C=CC(=C2)C1=NC(=NC=C1)NC1=NN(N=C1)C NLPLKXWLYFWCFF-UHFFFAOYSA-N 0.000 claims description 2
- VBFQZUJOKZAWJD-UHFFFAOYSA-N 4-[1-(3-methoxy-2,2-dimethylpropyl)benzotriazol-5-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound COCC(CN1N=NC2=C1C=CC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C)(C)C VBFQZUJOKZAWJD-UHFFFAOYSA-N 0.000 claims description 2
- JPMKSZAMMJUAAC-UHFFFAOYSA-N 4-[1-(4,4-difluorocyclohexyl)benzotriazol-5-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound FC1(CCC(CC1)N1N=NC2=C1C=CC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C)F JPMKSZAMMJUAAC-UHFFFAOYSA-N 0.000 claims description 2
- KNCFAJZUWNSXEV-UHFFFAOYSA-N 4-[1-(5-chloro-2,3-dihydro-1H-inden-1-yl)benzotriazol-5-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound ClC=1C=C2CCC(C2=CC=1)N1N=NC2=C1C=CC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C KNCFAJZUWNSXEV-UHFFFAOYSA-N 0.000 claims description 2
- MTIOMNMMKZGIHG-UHFFFAOYSA-N 4-[1-(azetidin-3-ylmethyl)benzotriazol-5-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound N1CC(C1)CN1N=NC2=C1C=CC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C MTIOMNMMKZGIHG-UHFFFAOYSA-N 0.000 claims description 2
- NGJRZAMQKFBJJH-UHFFFAOYSA-N 4-[1-(cyclopentylmethyl)benzotriazol-5-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound C1(CCCC1)CN1N=NC2=C1C=CC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C NGJRZAMQKFBJJH-UHFFFAOYSA-N 0.000 claims description 2
- UWEAQDARDSPZGN-UHFFFAOYSA-N 4-[1-[(1-methylazetidin-3-yl)methyl]benzotriazol-5-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound CN1N=CC=C1NC1=NC=CC(=N1)C1=CC2=C(N(N=N2)CC2CN(C2)C)C=C1 UWEAQDARDSPZGN-UHFFFAOYSA-N 0.000 claims description 2
- OHEXIZIOIZJBPW-UHFFFAOYSA-N 4-[1-[(1-methylcyclobutyl)methyl]benzotriazol-5-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound CN1N=CC=C1NC1=NC=CC(=N1)C1=CC2=C(N(N=N2)CC2(CCC2)C)C=C1 OHEXIZIOIZJBPW-UHFFFAOYSA-N 0.000 claims description 2
- UOUKLFVLAVBJBH-UHFFFAOYSA-N 4-[1-[(2,3-difluorophenyl)methyl]benzotriazol-5-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound FC1=C(CN2N=NC3=C2C=CC(=C3)C2=NC(=NC=C2)NC2=CC=NN2C)C=CC=C1F UOUKLFVLAVBJBH-UHFFFAOYSA-N 0.000 claims description 2
- DJJBBROQSIXUBK-UHFFFAOYSA-N 4-[1-[(2,4-difluorophenyl)methyl]benzotriazol-5-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound FC1=C(CN2N=NC3=C2C=CC(=C3)C2=NC(=NC=C2)NC2=CC=NN2C)C=CC(=C1)F DJJBBROQSIXUBK-UHFFFAOYSA-N 0.000 claims description 2
- YMBKGBVKSHWGLY-UHFFFAOYSA-N 4-[1-[(2-chloropyridin-3-yl)methyl]benzotriazol-5-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound ClC1=NC=CC=C1CN1N=NC2=C1C=CC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C YMBKGBVKSHWGLY-UHFFFAOYSA-N 0.000 claims description 2
- PHCMAIABBYAIMF-UHFFFAOYSA-N 4-[1-[(2-methoxypyridin-3-yl)methyl]benzotriazol-5-yl]-N-(2-methylpyrazol-3-yl)pyridin-2-amine Chemical compound COC1=NC=CC=C1CN1N=NC2=C1C=CC(=C2)C1=CC(=NC=C1)NC1=CC=NN1C PHCMAIABBYAIMF-UHFFFAOYSA-N 0.000 claims description 2
- RNANUNHHDRQTEK-UHFFFAOYSA-N 4-[1-[(2-methoxypyridin-3-yl)methyl]benzotriazol-5-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound COC1=NC=CC=C1CN1N=NC2=C1C=CC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C RNANUNHHDRQTEK-UHFFFAOYSA-N 0.000 claims description 2
- WUHIAFOOFWMCNG-UHFFFAOYSA-N 4-[1-[(3,3-difluorocyclobutyl)methyl]benzotriazol-5-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound FC1(CC(C1)CN1N=NC2=C1C=CC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C)F WUHIAFOOFWMCNG-UHFFFAOYSA-N 0.000 claims description 2
- ZNESWAPZNLENAL-UHFFFAOYSA-N 4-[1-[(3,5-difluoropyridin-2-yl)methyl]benzotriazol-5-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound FC=1C(=NC=C(C=1)F)CN1N=NC2=C1C=CC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C ZNESWAPZNLENAL-UHFFFAOYSA-N 0.000 claims description 2
- GJIYHDRAQJLQGF-UHFFFAOYSA-N 4-[1-[(3-chloro-4-fluorophenyl)methyl]benzotriazol-5-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound ClC=1C=C(CN2N=NC3=C2C=CC(=C3)C2=NC(=NC=C2)NC2=CC=NN2C)C=CC=1F GJIYHDRAQJLQGF-UHFFFAOYSA-N 0.000 claims description 2
- UMSARLKOIDUXPC-UHFFFAOYSA-N 4-[1-[(3-fluoro-4-methoxyphenyl)methyl]benzotriazol-5-yl]-N-(1,3,5-trimethylpyrazol-4-yl)pyrimidin-2-amine Chemical compound FC=1C=C(CN2N=NC3=C2C=CC(=C3)C2=NC(=NC=C2)NC=2C(=NN(C=2C)C)C)C=CC=1OC UMSARLKOIDUXPC-UHFFFAOYSA-N 0.000 claims description 2
- WLFAUFCRGUTCCE-UHFFFAOYSA-N 4-[1-[(3-fluoro-4-methoxyphenyl)methyl]benzotriazol-5-yl]-N-(1-methylpyrazol-4-yl)pyrimidin-2-amine Chemical compound FC=1C=C(CN2N=NC3=C2C=CC(=C3)C2=NC(=NC=C2)NC=2C=NN(C=2)C)C=CC=1OC WLFAUFCRGUTCCE-UHFFFAOYSA-N 0.000 claims description 2
- ATAAWMQTBNHXAP-UHFFFAOYSA-N 4-[1-[(3-fluoro-4-methoxyphenyl)methyl]benzotriazol-5-yl]-N-(1-methyltetrazol-5-yl)pyrimidin-2-amine Chemical compound FC=1C=C(CN2N=NC3=C2C=CC(=C3)C2=NC(=NC=C2)NC2=NN=NN2C)C=CC=1OC ATAAWMQTBNHXAP-UHFFFAOYSA-N 0.000 claims description 2
- CFBHLEQUNLBURB-UHFFFAOYSA-N 4-[1-[(3-fluoro-4-methoxyphenyl)methyl]benzotriazol-5-yl]-N-(2-methyl-1-morpholin-4-ylpropan-2-yl)pyrimidin-2-amine Chemical compound FC=1C=C(CN2N=NC3=C2C=CC(=C3)C2=NC(=NC=C2)NC(CN2CCOCC2)(C)C)C=CC=1OC CFBHLEQUNLBURB-UHFFFAOYSA-N 0.000 claims description 2
- ZWXVNVADSMSTTE-UHFFFAOYSA-N 4-[1-[(3-fluoro-4-methoxyphenyl)methyl]benzotriazol-5-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound COC1=C(F)C=C(CN2N=NC3=CC(=CC=C23)C2=CC=NC(NC3=CC=NN3C)=N2)C=C1 ZWXVNVADSMSTTE-UHFFFAOYSA-N 0.000 claims description 2
- GQEFWRSSZVDHAP-UHFFFAOYSA-N 4-[1-[(3-fluoro-4-methoxyphenyl)methyl]benzotriazol-5-yl]-N-(2-methyltetrazol-5-yl)pyrimidin-2-amine Chemical compound FC=1C=C(CN2N=NC3=C2C=CC(=C3)C2=NC(=NC=C2)NC=2N=NN(N=2)C)C=CC=1OC GQEFWRSSZVDHAP-UHFFFAOYSA-N 0.000 claims description 2
- PEBKJMXXKVSMCF-UHFFFAOYSA-N 4-[1-[(3-fluoro-4-methoxyphenyl)methyl]benzotriazol-5-yl]-N-(2-methyltriazol-4-yl)pyrimidin-2-amine Chemical compound FC=1C=C(CN2N=NC3=C2C=CC(=C3)C2=NC(=NC=C2)NC2=NN(N=C2)C)C=CC=1OC PEBKJMXXKVSMCF-UHFFFAOYSA-N 0.000 claims description 2
- RUSOAKSAOIKIGQ-UHFFFAOYSA-N 4-[1-[(3-fluoro-4-methoxyphenyl)methyl]benzotriazol-5-yl]-N-(3-methyloxetan-3-yl)pyrimidin-2-amine Chemical compound FC=1C=C(CN2N=NC3=C2C=CC(=C3)C2=NC(=NC=C2)NC2(COC2)C)C=CC=1OC RUSOAKSAOIKIGQ-UHFFFAOYSA-N 0.000 claims description 2
- DELLFCJXIOYWOL-UHFFFAOYSA-N 4-[1-[(3-fluoro-4-methoxyphenyl)methyl]benzotriazol-5-yl]-N-(oxan-4-yl)pyrimidin-2-amine Chemical compound FC=1C=C(CN2N=NC3=C2C=CC(=C3)C2=NC(=NC=C2)NC2CCOCC2)C=CC=1OC DELLFCJXIOYWOL-UHFFFAOYSA-N 0.000 claims description 2
- INZTUPCJAKOHEX-UHFFFAOYSA-N 4-[1-[(3-fluoro-4-methoxyphenyl)methyl]benzotriazol-5-yl]-N-(oxetan-3-yl)pyrimidin-2-amine Chemical compound FC=1C=C(CN2N=NC3=C2C=CC(=C3)C2=NC(=NC=C2)NC2COC2)C=CC=1OC INZTUPCJAKOHEX-UHFFFAOYSA-N 0.000 claims description 2
- SCYIVUXTDOJNSM-UHFFFAOYSA-N 4-[1-[(3-fluoro-4-methoxyphenyl)methyl]benzotriazol-5-yl]-N-(oxetan-3-ylmethyl)pyrimidin-2-amine Chemical compound COC1=C(F)C=C(CN2N=NC3=CC(=CC=C23)C2=CC=NC(NCC3COC3)=N2)C=C1 SCYIVUXTDOJNSM-UHFFFAOYSA-N 0.000 claims description 2
- PGISWDDWZOCKPJ-IEBWSBKVSA-N 4-[1-[(3-fluoro-4-methoxyphenyl)methyl]benzotriazol-5-yl]-N-[(3S,4R)-3-fluorooxan-4-yl]pyrimidin-2-amine Chemical compound FC=1C=C(CN2N=NC3=C2C=CC(=C3)C2=NC(=NC=C2)N[C@H]2[C@@H](COCC2)F)C=CC=1OC PGISWDDWZOCKPJ-IEBWSBKVSA-N 0.000 claims description 2
- PGISWDDWZOCKPJ-MJGOQNOKSA-N 4-[1-[(3-fluoro-4-methoxyphenyl)methyl]benzotriazol-5-yl]-N-[(3S,4S)-3-fluorooxan-4-yl]pyrimidin-2-amine Chemical compound FC=1C=C(CN2N=NC3=C2C=CC(=C3)C2=NC(=NC=C2)N[C@@H]2[C@@H](COCC2)F)C=CC=1OC PGISWDDWZOCKPJ-MJGOQNOKSA-N 0.000 claims description 2
- JRTLWXHCYUTTAH-UHFFFAOYSA-N 4-[1-[(3-fluoro-4-methoxyphenyl)methyl]benzotriazol-5-yl]-N-propan-2-ylpyrimidin-2-amine Chemical compound COC1=C(F)C=C(CN2N=NC3=CC(=CC=C23)C2=CC=NC(NC(C)C)=N2)C=C1 JRTLWXHCYUTTAH-UHFFFAOYSA-N 0.000 claims description 2
- SNBMQFGFYCXPOP-UHFFFAOYSA-N 4-[1-[(3-fluorophenyl)methyl]benzotriazol-5-yl]-N-(oxan-4-yl)pyrimidin-2-amine Chemical compound FC=1C=C(CN2N=NC3=C2C=CC(=C3)C2=NC(=NC=C2)NC2CCOCC2)C=CC=1 SNBMQFGFYCXPOP-UHFFFAOYSA-N 0.000 claims description 2
- WCFNSPOYDZVXJF-UHFFFAOYSA-N 4-[1-[(3-methoxypyridin-2-yl)methyl]benzotriazol-5-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound COC=1C(=NC=CC=1)CN1N=NC2=C1C=CC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C WCFNSPOYDZVXJF-UHFFFAOYSA-N 0.000 claims description 2
- OIPSPLNIIAJKKB-LJQANCHMSA-N 4-[1-[(3R)-1-[(2-fluoro-6-methoxyphenyl)methyl]piperidin-3-yl]benzotriazol-5-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound FC1=C(CN2C[C@@H](CCC2)N2N=NC3=C2C=CC(=C3)C2=NC(=NC=C2)NC2=CC=NN2C)C(=CC=C1)OC OIPSPLNIIAJKKB-LJQANCHMSA-N 0.000 claims description 2
- BLYMFLYDSBKDJY-GOSISDBHSA-N 4-[1-[(3R)-5,5-difluoro-1-[(2-fluoro-6-methoxyphenyl)methyl]piperidin-3-yl]benzotriazol-5-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound FC1(C[C@H](CN(C1)CC1=C(C=CC=C1OC)F)N1N=NC2=C1C=CC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C)F BLYMFLYDSBKDJY-GOSISDBHSA-N 0.000 claims description 2
- XHYWJMUZFZRWCW-CYBMUJFWSA-N 4-[1-[(3R)-5,5-difluoropiperidin-3-yl]benzotriazol-5-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound FC1(C[C@H](CNC1)N1N=NC2=C1C=CC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C)F XHYWJMUZFZRWCW-CYBMUJFWSA-N 0.000 claims description 2
- IIYIZSKAFXWJAJ-BWKNWUBXSA-N 4-[1-[(3R,4S)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]benzotriazol-5-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound FC1=CC=C(C=C1)[C@@H]1[C@H](CN(C1)CCOC)N1N=NC2=C1C=CC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C IIYIZSKAFXWJAJ-BWKNWUBXSA-N 0.000 claims description 2
- CMKPUGYJIOMANA-KSFYIVLOSA-N 4-[1-[(3S,4R)-4-(3,4-difluorophenyl)pyrrolidin-3-yl]benzotriazol-5-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound FC=1C=C(C=CC=1F)[C@H]1[C@@H](CNC1)N1N=NC2=C1C=CC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C CMKPUGYJIOMANA-KSFYIVLOSA-N 0.000 claims description 2
- IIYIZSKAFXWJAJ-SQJMNOBHSA-N 4-[1-[(3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]benzotriazol-5-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound FC1=CC=C(C=C1)[C@H]1[C@@H](CN(C1)CCOC)N1N=NC2=C1C=CC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C IIYIZSKAFXWJAJ-SQJMNOBHSA-N 0.000 claims description 2
- FTIYQUUZECWCCC-UHFFFAOYSA-N 4-[1-[(4,4-difluorocyclohexyl)methyl]benzotriazol-5-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound FC1(CCC(CC1)CN1N=NC2=C1C=CC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C)F FTIYQUUZECWCCC-UHFFFAOYSA-N 0.000 claims description 2
- LCISAHCKDOXWQG-UHFFFAOYSA-N 4-[1-[(4-chloro-3-fluorophenyl)methyl]benzotriazol-5-yl]-N-(oxan-4-yl)pyrimidin-2-amine Chemical compound ClC1=C(C=C(CN2N=NC3=C2C=CC(=C3)C2=NC(=NC=C2)NC2CCOCC2)C=C1)F LCISAHCKDOXWQG-UHFFFAOYSA-N 0.000 claims description 2
- UUIIZSAKJLONIX-UHFFFAOYSA-N 4-[1-[(4-chlorophenyl)methyl]benzotriazol-5-yl]-N-(oxan-4-yl)pyrimidin-2-amine Chemical compound ClC1=CC=C(CN2N=NC3=C2C=CC(=C3)C2=NC(=NC=C2)NC2CCOCC2)C=C1 UUIIZSAKJLONIX-UHFFFAOYSA-N 0.000 claims description 2
- KRVSVNHKRSKZEX-UHFFFAOYSA-N 4-[1-[(4-fluorophenyl)methyl]benzotriazol-5-yl]-N-(oxan-4-yl)pyrimidin-2-amine Chemical compound FC1=CC=C(CN2N=NC3=C2C=CC(=C3)C2=NC(=NC=C2)NC2CCOCC2)C=C1 KRVSVNHKRSKZEX-UHFFFAOYSA-N 0.000 claims description 2
- ZWYLUUFZYVONAH-DEOSSOPVSA-N 4-[1-[(S)-(3-fluoro-4-methoxyphenyl)-(1-methylimidazol-2-yl)methyl]benzotriazol-5-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound FC=1C=C(C=CC=1OC)[C@H](N1N=NC2=C1C=CC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C)C=1N(C=CN=1)C ZWYLUUFZYVONAH-DEOSSOPVSA-N 0.000 claims description 2
- TYPTUANWOPRSIP-VWLOTQADSA-N 4-[1-[(S)-(3-fluoro-4-methoxyphenyl)-(1-methylpyrazol-4-yl)methyl]benzotriazol-5-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound FC=1C=C(C=CC=1OC)[C@H](N1N=NC2=C1C=CC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C)C=1C=NN(C=1)C TYPTUANWOPRSIP-VWLOTQADSA-N 0.000 claims description 2
- DICRIHAIHCXZPD-DEOSSOPVSA-N 4-[1-[(S)-(3-fluoro-4-methoxyphenyl)-(3-methyltriazol-4-yl)methyl]benzotriazol-5-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound FC=1C=C(C=CC=1OC)[C@H](N1N=NC2=C1C=CC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C)C1=CN=NN1C DICRIHAIHCXZPD-DEOSSOPVSA-N 0.000 claims description 2
- FEJWNRGVMBNUTL-UHFFFAOYSA-N 4-[1-[1-(4-chloro-3-fluorophenyl)-2-(dimethylamino)ethyl]benzotriazol-5-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound ClC1=C(C=C(C=C1)C(CN(C)C)N1N=NC2=C1C=CC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C)F FEJWNRGVMBNUTL-UHFFFAOYSA-N 0.000 claims description 2
- WPILZZMNUBPRIC-UHFFFAOYSA-N 4-[1-[1-(4-chloro-3-fluorophenyl)-2-pyrrolidin-1-ylethyl]benzotriazol-5-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound ClC1=C(C=C(C=C1)C(CN1CCCC1)N1N=NC2=C1C=CC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C)F WPILZZMNUBPRIC-UHFFFAOYSA-N 0.000 claims description 2
- JHWPQMGGDVFJGC-UHFFFAOYSA-N 4-[1-[2-(4-chloropyrazol-1-yl)ethyl]benzotriazol-5-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound ClC=1C=NN(C=1)CCN1N=NC2=C1C=CC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C JHWPQMGGDVFJGC-UHFFFAOYSA-N 0.000 claims description 2
- FGRWLYZMOJFFIK-UHFFFAOYSA-N 4-[1-[4-(3-fluorophenyl)piperidin-3-yl]benzotriazol-5-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound FC=1C=C(C=CC=1)C1C(CNCC1)N1N=NC2=C1C=CC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C FGRWLYZMOJFFIK-UHFFFAOYSA-N 0.000 claims description 2
- COZQTHNQBPRNRE-UHFFFAOYSA-N 4-[1-[4-(4-fluorophenyl)piperidin-3-yl]benzotriazol-5-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound FC1=CC=C(C=C1)C1C(CNCC1)N1N=NC2=C1C=CC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C COZQTHNQBPRNRE-UHFFFAOYSA-N 0.000 claims description 2
- VPDMBSXQIINLGC-UHFFFAOYSA-N 4-[1-[[1-(ethoxymethyl)cyclopropyl]methyl]benzotriazol-5-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound C(C)OCC1(CC1)CN1N=NC2=C1C=CC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C VPDMBSXQIINLGC-UHFFFAOYSA-N 0.000 claims description 2
- UDDCKUAVLOPOPE-UHFFFAOYSA-N 4-[1-[[4-(difluoromethoxy)phenyl]methyl]benzotriazol-5-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound FC(OC1=CC=C(CN2N=NC3=C2C=CC(=C3)C2=NC(=NC=C2)NC2=CC=NN2C)C=C1)F UDDCKUAVLOPOPE-UHFFFAOYSA-N 0.000 claims description 2
- UMHBFPZISHIGEF-UHFFFAOYSA-N 4-[3-(2-methylpropyl)triazolo[4,5-b]pyridin-6-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical class C(C(C)C)N1N=NC=2C1=NC=C(C=2)C1=NC(=NC=C1)NC1=CC=NN1C UMHBFPZISHIGEF-UHFFFAOYSA-N 0.000 claims description 2
- CLUNBPLUFHEOKP-UHFFFAOYSA-N 4-[3-[(2-methoxypyridin-3-yl)methyl]triazolo[4,5-b]pyridin-6-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound COC1=NC=CC=C1CN1N=NC=2C1=NC=C(C=2)C1=NC(=NC=C1)NC1=CC=NN1C CLUNBPLUFHEOKP-UHFFFAOYSA-N 0.000 claims description 2
- JSZMQOSWJJFSJA-UHFFFAOYSA-N 4-[3-[(3-chloro-4-fluorophenyl)methyl]triazolo[4,5-b]pyridin-6-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound ClC=1C=C(CN2N=NC=3C2=NC=C(C=3)C2=NC(=NC=C2)NC2=CC=NN2C)C=CC=1F JSZMQOSWJJFSJA-UHFFFAOYSA-N 0.000 claims description 2
- NUQJCKNSJKSSJF-UHFFFAOYSA-N 4-[3-[(3-chlorophenyl)methyl]triazolo[4,5-b]pyridin-6-yl]-N-(2-methylpyrazol-3-yl)pyridin-2-amine Chemical compound ClC=1C=C(CN2N=NC=3C2=NC=C(C=3)C2=CC(=NC=C2)NC2=CC=NN2C)C=CC=1 NUQJCKNSJKSSJF-UHFFFAOYSA-N 0.000 claims description 2
- IZVYCUNJZVTQPR-UHFFFAOYSA-N 4-[3-[(3-chlorophenyl)methyl]triazolo[4,5-b]pyridin-6-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound ClC=1C=C(CN2N=NC=3C2=NC=C(C=3)C2=NC(=NC=C2)NC2=CC=NN2C)C=CC=1 IZVYCUNJZVTQPR-UHFFFAOYSA-N 0.000 claims description 2
- FTBFTPPEQKFETA-UHFFFAOYSA-N 4-[3-[(3-fluoro-4-methoxyphenyl)methyl]triazolo[4,5-b]pyridin-6-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound FC=1C=C(CN2N=NC=3C2=NC=C(C=3)C2=NC(=NC=C2)NC2=CC=NN2C)C=CC=1OC FTBFTPPEQKFETA-UHFFFAOYSA-N 0.000 claims description 2
- AWPULHLSAFYKJO-UHFFFAOYSA-N 4-[3-[(4-chloro-3-fluorophenyl)methyl]triazolo[4,5-b]pyridin-6-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound ClC1=C(C=C(CN2N=NC=3C2=NC=C(C=3)C2=NC(=NC=C2)NC2=CC=NN2C)C=C1)F AWPULHLSAFYKJO-UHFFFAOYSA-N 0.000 claims description 2
- CANGFXIPJSCYMS-UHFFFAOYSA-N 4-[3-[(4-chlorophenyl)methyl]triazolo[4,5-b]pyridin-6-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound ClC1=CC=C(CN2N=NC=3C2=NC=C(C=3)C2=NC(=NC=C2)NC2=CC=NN2C)C=C1 CANGFXIPJSCYMS-UHFFFAOYSA-N 0.000 claims description 2
- RGJDGVANAUOINV-UHFFFAOYSA-N 4-[3-[2-(3-chlorophenyl)ethyl]triazolo[4,5-b]pyridin-6-yl]-N-(2-methylpyrazol-3-yl)pyrimidin-2-amine Chemical compound ClC=1C=C(CCN2N=NC=3C2=NC=C(C=3)C2=NC(=NC=C2)NC2=CC=NN2C)C=CC=1 RGJDGVANAUOINV-UHFFFAOYSA-N 0.000 claims description 2
- BLVSKKNAQDSQGW-UHFFFAOYSA-N 4-[5-[2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]benzotriazol-1-yl]butan-2-ol Chemical compound CN1N=CC=C1NC1=NC=CC(=N1)C1=CC2=C(N(N=N2)CCC(C)O)C=C1 BLVSKKNAQDSQGW-UHFFFAOYSA-N 0.000 claims description 2
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 claims description 2
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims description 2
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 2
- 208000003200 Adenoma Diseases 0.000 claims description 2
- 206010001233 Adenoma benign Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 208000018501 Lymphatic disease Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 claims description 2
- LCHXJIRWSWSVCY-UHFFFAOYSA-N N-(1,3-dimethylpyrazol-4-yl)-4-[1-[(3-fluoro-4-methoxyphenyl)methyl]benzotriazol-5-yl]pyrimidin-2-amine Chemical compound CN1N=C(C(=C1)NC1=NC=CC(=N1)C1=CC2=C(N(N=N2)CC2=CC(=C(C=C2)OC)F)C=C1)C LCHXJIRWSWSVCY-UHFFFAOYSA-N 0.000 claims description 2
- CFCKXSDPAXMVSR-UHFFFAOYSA-N N-(2-methylpyrazol-3-yl)-4-(1-piperidin-4-ylbenzotriazol-5-yl)pyrimidin-2-amine Chemical compound CN1N=CC=C1NC1=NC=CC(=N1)C1=CC2=C(N(N=N2)C2CCNCC2)C=C1 CFCKXSDPAXMVSR-UHFFFAOYSA-N 0.000 claims description 2
- MVZLECGHZHFFTD-UHFFFAOYSA-N N-(2-methylpyrazol-3-yl)-4-[1-(2-pyrazol-1-ylethyl)benzotriazol-5-yl]pyrimidin-2-amine Chemical compound N1(N=CC=C1)CCN1N=NC2=C1C=CC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C MVZLECGHZHFFTD-UHFFFAOYSA-N 0.000 claims description 2
- ULPQQCADMHBDKB-UHFFFAOYSA-N N-(2-methylpyrazol-3-yl)-4-[1-(3-propan-2-yloxypropyl)benzotriazol-5-yl]pyrimidin-2-amine Chemical compound C(C)(C)OCCCN1N=NC2=C1C=CC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C ULPQQCADMHBDKB-UHFFFAOYSA-N 0.000 claims description 2
- JNMSGICMXMRZJE-UHFFFAOYSA-N N-(2-methylpyrazol-3-yl)-4-[1-(5-methyl-2-pyridin-2-ylpyrazol-3-yl)benzotriazol-5-yl]pyrimidin-2-amine Chemical compound CC1=NN(C(=C1)N1N=NC2=C1C=CC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C)C1=NC=CC=C1 JNMSGICMXMRZJE-UHFFFAOYSA-N 0.000 claims description 2
- YPAJNKZFCKDPQR-UHFFFAOYSA-N N-(2-methylpyrazol-3-yl)-4-[1-(oxan-2-ylmethyl)benzotriazol-5-yl]pyrimidin-2-amine Chemical compound CN1N=CC=C1NC1=NC=CC(=N1)C1=CC2=C(N(N=N2)CC2OCCCC2)C=C1 YPAJNKZFCKDPQR-UHFFFAOYSA-N 0.000 claims description 2
- KIPCQLKKHFEOJB-UHFFFAOYSA-N N-(2-methylpyrazol-3-yl)-4-[1-(oxetan-3-ylmethyl)benzotriazol-5-yl]pyrimidin-2-amine Chemical compound CN1N=CC=C1NC1=NC=CC(=N1)C1=CC2=C(N(N=N2)CC2COC2)C=C1 KIPCQLKKHFEOJB-UHFFFAOYSA-N 0.000 claims description 2
- SGTHNPTUGKOIDO-UHFFFAOYSA-N N-(2-methylpyrazol-3-yl)-4-[1-[(1-methylpyrazol-3-yl)methyl]benzotriazol-5-yl]pyrimidin-2-amine Chemical compound CN1N=C(C=C1)CN1N=NC2=C1C=CC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C SGTHNPTUGKOIDO-UHFFFAOYSA-N 0.000 claims description 2
- JWKZWQDAXAYYHJ-UHFFFAOYSA-N N-(2-methylpyrazol-3-yl)-4-[1-[(2-methylpyrazol-3-yl)methyl]benzotriazol-5-yl]pyrimidin-2-amine Chemical compound CN1N=CC=C1NC1=NC=CC(=N1)C1=CC2=C(N(N=N2)CC2=CC=NN2C)C=C1 JWKZWQDAXAYYHJ-UHFFFAOYSA-N 0.000 claims description 2
- UGGSFBWAWVORRB-UHFFFAOYSA-N N-(2-methylpyrazol-3-yl)-4-[1-[(2-methylpyridin-3-yl)methyl]benzotriazol-5-yl]pyridin-2-amine Chemical compound CN1N=CC=C1NC1=NC=CC(=C1)C1=CC2=C(N(N=N2)CC=2C(=NC=CC=2)C)C=C1 UGGSFBWAWVORRB-UHFFFAOYSA-N 0.000 claims description 2
- LOJYXQXRLLTFSL-UHFFFAOYSA-N N-(2-methylpyrazol-3-yl)-4-[1-[(2-methylpyridin-3-yl)methyl]benzotriazol-5-yl]pyrimidin-2-amine Chemical compound CN1N=CC=C1NC1=NC=CC(=N1)C1=CC2=C(N(N=N2)CC=2C(=NC=CC=2)C)C=C1 LOJYXQXRLLTFSL-UHFFFAOYSA-N 0.000 claims description 2
- WGAUMBMLINTWGC-UHFFFAOYSA-N N-(2-methylpyrazol-3-yl)-4-[1-[(4-phenylpiperidin-4-yl)methyl]benzotriazol-5-yl]pyrimidin-2-amine Chemical compound CN1N=CC=C1NC1=NC=CC(=N1)C1=CC2=C(N(N=N2)CC2(CCNCC2)C2=CC=CC=C2)C=C1 WGAUMBMLINTWGC-UHFFFAOYSA-N 0.000 claims description 2
- UNEWFOUTVALHCM-UHFFFAOYSA-N N-(2-methylpyrazol-3-yl)-4-[1-[(6-methylpyridin-2-yl)methyl]benzotriazol-5-yl]pyrimidin-2-amine Chemical compound CN1N=CC=C1NC1=NC=CC(=N1)C1=CC2=C(N(N=N2)CC2=NC(=CC=C2)C)C=C1 UNEWFOUTVALHCM-UHFFFAOYSA-N 0.000 claims description 2
- SFOYNGVBHGRWAZ-UHFFFAOYSA-N N-(2-methylpyrazol-3-yl)-4-[1-[2-(4-methylpyrazol-1-yl)ethyl]benzotriazol-5-yl]pyrimidin-2-amine Chemical compound CC=1C=NN(C=1)CCN1N=NC2=C1C=CC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C SFOYNGVBHGRWAZ-UHFFFAOYSA-N 0.000 claims description 2
- WYCHYCJYPPLXEY-UHFFFAOYSA-N N-(2-methylpyrazol-3-yl)-4-[1-[[1-(2,2,2-trifluoroethyl)azetidin-3-yl]methyl]benzotriazol-5-yl]pyrimidin-2-amine Chemical compound CN1N=CC=C1NC1=NC=CC(=N1)C1=CC2=C(N(N=N2)CC2CN(C2)CC(F)(F)F)C=C1 WYCHYCJYPPLXEY-UHFFFAOYSA-N 0.000 claims description 2
- WXUFMURMOOEQNE-UHFFFAOYSA-N N-(2-methylpyrazol-3-yl)-4-[1-[[1-[4-(trifluoromethoxy)phenyl]cyclopropyl]methyl]benzotriazol-5-yl]pyrimidin-2-amine Chemical compound CN1N=CC=C1NC1=NC=CC(=N1)C1=CC2=C(N(N=N2)CC2(CC2)C2=CC=C(C=C2)OC(F)(F)F)C=C1 WXUFMURMOOEQNE-UHFFFAOYSA-N 0.000 claims description 2
- MQQMQUVUGUFADE-UHFFFAOYSA-N N-(2-methylpyrazol-3-yl)-4-[1-[[2-(trifluoromethyl)phenyl]methyl]benzotriazol-5-yl]pyrimidin-2-amine Chemical compound CN1N=CC=C1NC1=NC=CC(=N1)C1=CC2=C(N(N=N2)CC2=C(C=CC=C2)C(F)(F)F)C=C1 MQQMQUVUGUFADE-UHFFFAOYSA-N 0.000 claims description 2
- XRTQOTNZRDAPKB-UHFFFAOYSA-N N-(2-methylpyrazol-3-yl)-4-[1-[[6-(trifluoromethyl)pyridin-2-yl]methyl]benzotriazol-5-yl]pyrimidin-2-amine Chemical compound CN1N=CC=C1NC1=NC=CC(=N1)C1=CC2=C(N(N=N2)CC2=NC(=CC=C2)C(F)(F)F)C=C1 XRTQOTNZRDAPKB-UHFFFAOYSA-N 0.000 claims description 2
- KLYNRJMICWCASP-UHFFFAOYSA-N N-(5-cyclopropyl-2-methylpyrazol-3-yl)-4-[1-[(3-fluoro-4-methoxyphenyl)methyl]benzotriazol-5-yl]pyrimidin-2-amine Chemical compound C1(CC1)C1=NN(C(=C1)NC1=NC=CC(=N1)C1=CC2=C(N(N=N2)CC2=CC(=C(C=C2)OC)F)C=C1)C KLYNRJMICWCASP-UHFFFAOYSA-N 0.000 claims description 2
- VKMQDQPWUXIETL-UHFFFAOYSA-N N-(cyclopropylmethyl)-4-[1-[(3-fluoro-4-methoxyphenyl)methyl]benzotriazol-5-yl]pyrimidin-2-amine Chemical compound C1(CC1)CNC1=NC=CC(=N1)C1=CC2=C(N(N=N2)CC2=CC(=C(C=C2)OC)F)C=C1 VKMQDQPWUXIETL-UHFFFAOYSA-N 0.000 claims description 2
- HYTSOTPPMKNWMJ-UHFFFAOYSA-N N-[4-[1-[(3-fluoro-4-methoxyphenyl)methyl]benzotriazol-5-yl]pyrimidin-2-yl]-5-methyl-1,3,4-thiadiazol-2-amine Chemical compound COC1=C(F)C=C(CN2N=NC3=CC(=CC=C23)C2=CC=NC(NC3=NN=C(C)S3)=N2)C=C1 HYTSOTPPMKNWMJ-UHFFFAOYSA-N 0.000 claims description 2
- DBTNWYQXIDYQDN-UHFFFAOYSA-N N-cyclobutyl-4-[1-[(3-fluoro-4-methoxyphenyl)methyl]benzotriazol-5-yl]pyrimidin-2-amine Chemical compound C1(CCC1)NC1=NC=CC(=N1)C1=CC2=C(N(N=N2)CC2=CC(=C(C=C2)OC)F)C=C1 DBTNWYQXIDYQDN-UHFFFAOYSA-N 0.000 claims description 2
- TYEHWAVSVKPHGH-UHFFFAOYSA-N N-cyclopropyl-4-[1-[(3-fluoro-4-methoxyphenyl)methyl]benzotriazol-5-yl]pyrimidin-2-amine Chemical compound C1(CC1)NC1=NC=CC(=N1)C1=CC2=C(N(N=N2)CC2=CC(=C(C=C2)OC)F)C=C1 TYEHWAVSVKPHGH-UHFFFAOYSA-N 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 claims description 2
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000002615 epidermis Anatomy 0.000 claims description 2
- 230000003325 follicular Effects 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 2
- 208000018555 lymphatic system disease Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
- 208000025113 myeloid leukemia Diseases 0.000 claims description 2
- 125000003566 oxetanyl group Chemical group 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 2
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 208000000649 small cell carcinoma Diseases 0.000 claims description 2
- 208000001608 teratocarcinoma Diseases 0.000 claims description 2
- QUERMGFVJPRMJL-UHFFFAOYSA-N tert-butyl azetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC1 QUERMGFVJPRMJL-UHFFFAOYSA-N 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 230000001548 androgenic effect Effects 0.000 claims 10
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- RIKMMFOAQPJVMX-UHFFFAOYSA-N fomepizole Chemical compound CC=1C=NNC=1 RIKMMFOAQPJVMX-UHFFFAOYSA-N 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 208000003849 large cell carcinoma Diseases 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 description 10
- 0 *c(c(-c1c(*)c(N)c(N(*)N)nc1)c1)cnc1N* Chemical compound *c(c(-c1c(*)c(N)c(N(*)N)nc1)c1)cnc1N* 0.000 description 3
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361922045P | 2013-12-30 | 2013-12-30 | |
| US61/922,045 | 2013-12-30 | ||
| PCT/US2014/072547 WO2015103133A1 (en) | 2013-12-30 | 2014-12-29 | Serine/threonine kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017500364A JP2017500364A (ja) | 2017-01-05 |
| JP2017500364A5 true JP2017500364A5 (cg-RX-API-DMAC10.html) | 2019-01-24 |
| JP6487925B2 JP6487925B2 (ja) | 2019-03-20 |
Family
ID=52355260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016542969A Active JP6487925B2 (ja) | 2013-12-30 | 2014-12-29 | セリン／トレオニンキナーゼ阻害剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US9763942B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3089788B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP6487925B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR102379517B1 (cg-RX-API-DMAC10.html) |
| CN (1) | CN105848723B (cg-RX-API-DMAC10.html) |
| BR (1) | BR112016015235A2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2934679C (cg-RX-API-DMAC10.html) |
| MX (1) | MX370906B (cg-RX-API-DMAC10.html) |
| WO (1) | WO2015103133A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY191936A (en) * | 2012-03-01 | 2022-07-19 | Genentech Inc | Serine/threonine kinase inhibitors |
| CN104755478B (zh) | 2012-10-16 | 2017-10-10 | 霍夫曼-拉罗奇有限公司 | 丝氨酸/苏氨酸激酶抑制剂 |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| BR112016012844B1 (pt) | 2013-12-06 | 2023-01-10 | Genentech, Inc | Composto e composições farmacêuticas |
| JP6642942B2 (ja) | 2013-12-30 | 2020-02-12 | アレイ バイオファーマ、インコーポレイテッド | セリン／トレオニンキナーゼ阻害剤 |
| WO2015103133A1 (en) | 2013-12-30 | 2015-07-09 | Genentech, Inc. | Serine/threonine kinase inhibitors |
| CA3003549A1 (en) | 2015-11-09 | 2017-05-18 | Astrazeneca Ab | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer |
| EP3443114A1 (en) | 2016-04-15 | 2019-02-20 | H. Hoffnabb-La Roche Ag | Diagnostic and therapeutic methods for cancer |
| US10658802B2 (en) | 2016-06-24 | 2020-05-19 | Gyrus Acmi, Inc. | Gravity plug and connector |
| US11390609B2 (en) * | 2017-06-30 | 2022-07-19 | Beijing Tide Pharmaceutical Co., Ltd. | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof |
| MX2020002553A (es) | 2017-09-08 | 2020-07-22 | Hoffmann La Roche | Metodos de diagnostico y terapeuticos para el cancer. |
| EP3752200A1 (en) | 2018-02-13 | 2020-12-23 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
| ES3021205T3 (en) | 2018-04-26 | 2025-05-26 | Pfizer | 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors |
| WO2020192750A1 (zh) | 2019-03-28 | 2020-10-01 | 江苏恒瑞医药股份有限公司 | 噻吩并杂环类衍生物、其制备方法及其在医药上的应用 |
| CA3135070A1 (en) | 2019-03-29 | 2020-10-08 | Jiangsu Hengrui Medicine Co., Ltd. | Pyrroloheterocyclic derivative, preparation method therefor, and application thereof in medicine |
| WO2020238776A1 (zh) | 2019-05-24 | 2020-12-03 | 江苏恒瑞医药股份有限公司 | 取代的稠合双环类衍生物、其制备方法及其在医药上的应用 |
| CN110627775B (zh) * | 2019-10-24 | 2026-01-30 | 特科罗生物科技(成都)有限公司 | 一种小分子化合物 |
| WO2022068860A1 (zh) | 2020-09-29 | 2022-04-07 | 江苏恒瑞医药股份有限公司 | 一种吡咯并杂环类衍生物的晶型及其制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2379016A (en) * | 2001-07-27 | 2003-02-26 | Hewlett Packard Co | Portable apparatus monitoring reaction of user to music |
| DE102008037790A1 (de) * | 2008-08-14 | 2010-02-18 | Merck Patent Gmbh | Bicyclische Triazolderivate |
| WO2010141360A1 (en) * | 2009-06-05 | 2010-12-09 | Merck Sharp & Dohme Corp. | Biaryl benzotriazole derivatives |
| EP2681215B1 (en) * | 2011-02-28 | 2015-04-22 | Array Biopharma, Inc. | Serine/threonine kinase inhibitors |
| EP2739618B1 (en) | 2011-08-04 | 2015-09-16 | Array Biopharma, Inc. | Quinazoline compounds as serine/threonine kinase inhibitors |
| MY191936A (en) * | 2012-03-01 | 2022-07-19 | Genentech Inc | Serine/threonine kinase inhibitors |
| EP2888247B1 (en) | 2012-08-27 | 2020-03-25 | Array Biopharma, Inc. | Serine/threonine kinase inhibitors for the treatment of hyperproliferative diseases |
| BR112016012844B1 (pt) | 2013-12-06 | 2023-01-10 | Genentech, Inc | Composto e composições farmacêuticas |
| JP6642942B2 (ja) | 2013-12-30 | 2020-02-12 | アレイ バイオファーマ、インコーポレイテッド | セリン／トレオニンキナーゼ阻害剤 |
| WO2015103133A1 (en) | 2013-12-30 | 2015-07-09 | Genentech, Inc. | Serine/threonine kinase inhibitors |
-
2014
- 2014-12-29 WO PCT/US2014/072547 patent/WO2015103133A1/en not_active Ceased
- 2014-12-29 CN CN201480071237.7A patent/CN105848723B/zh active Active
- 2014-12-29 KR KR1020167018242A patent/KR102379517B1/ko active Active
- 2014-12-29 JP JP2016542969A patent/JP6487925B2/ja active Active
- 2014-12-29 CA CA2934679A patent/CA2934679C/en active Active
- 2014-12-29 MX MX2016008449A patent/MX370906B/es active IP Right Grant
- 2014-12-29 BR BR112016015235A patent/BR112016015235A2/pt not_active Application Discontinuation
- 2014-12-29 EP EP14827985.4A patent/EP3089788B1/en active Active
-
2016
- 2016-06-29 US US15/197,479 patent/US9763942B2/en active Active
-
2017
- 2017-08-23 US US15/684,733 patent/US10154995B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017500364A5 (cg-RX-API-DMAC10.html) | ||
| JP2017502049A5 (cg-RX-API-DMAC10.html) | ||
| RU2014139601A (ru) | Ингибиторы серин/треониновых киназ | |
| IL299180A (en) | 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors | |
| RU2017124425A (ru) | Производные 2,4-диоксо-хиназолин-6-сульфонамида в качестве ингибиторов parg | |
| JP2014531465A5 (cg-RX-API-DMAC10.html) | ||
| JP2015508828A5 (cg-RX-API-DMAC10.html) | ||
| JP2019530695A5 (cg-RX-API-DMAC10.html) | ||
| KR102396710B1 (ko) | 세린/트레오닌 키나제 저해제 | |
| JP2015528022A5 (cg-RX-API-DMAC10.html) | ||
| JP2019504854A5 (cg-RX-API-DMAC10.html) | ||
| IL258577A (en) | 2,4-dihydroxy-nicotinamides as apj agonists | |
| JP2018530591A5 (cg-RX-API-DMAC10.html) | ||
| JP2019519484A5 (cg-RX-API-DMAC10.html) | ||
| JP2019537571A5 (cg-RX-API-DMAC10.html) | ||
| SI3083586T1 (en) | The new carboxamides, the process of their manufacture, the pharmaceutical preparations they contain and their use for the manufacture of medicinal products | |
| JP2020515575A5 (cg-RX-API-DMAC10.html) | ||
| KR20180108822A (ko) | Nr2b-선택적 nmda 조절제로서 치환된 1,2,3-트라이아졸 | |
| RU2009138137A (ru) | Новые производные n-(8-гетероарилтетрагидронафталин-2-ил)-или n-(5-гетероарилхроман-3-ил)-карбоксамида для лечения боли | |
| RU2016137674A (ru) | Производные пиперидиндиона | |
| HRP20201746T1 (hr) | Aromatski derivati sulfonamida | |
| JP2011503166A5 (cg-RX-API-DMAC10.html) | ||
| JP2019504821A5 (cg-RX-API-DMAC10.html) | ||
| RU2015122414A (ru) | Соединения n-пирролидинилмочевины, n'-пиразолилмочевины, тиомочевины, гуанидина и цианогуанидина как ингибиторы киназы trka | |
| JP2016512259A5 (cg-RX-API-DMAC10.html) |